Loading...
•
Mar 31, 2021
Theravance Q1 2021 Earnings Report
Reported financial results for the first quarter of 2021 and provided a business update.
Key Takeaways
Theravance Biopharma reported its Q1 2021 financial results, highlighting the continued growth of GSK's TRELEGY and the performance of YUPELRI with partner Viatris, despite pandemic-associated headwinds. The company is focused on advancing its pipeline with four significant clinical readouts expected between now and Q1 2022.
2021 is on track to be a transformational year.
Commercial assets provide cash flow to invest in the clinical pipeline.
GSK’s TRELEGY continues an exceptional growth trajectory.
Advancing development of innovative and differentiated pipeline.
Theravance
Theravance
Forward Guidance
Theravance Biopharma is focused on advancing its pipeline with four significant clinical readouts expected between now and Q1 2022.